



**Figure S1** XPO1 expression levels and prognostic values of XPO1 (supplementary to *Figure 2*). (A) Kaplan-Meier analysis of the correlations of XPO1 expression in LIHC with (from left to right) OS, DSS, and PFI. (B) Kaplan-Meier analysis of the correlation of XPO1 expression in LUAD with PFI. (C) Kaplan-Meier analysis of the correlations of XPO1 expression in PRAD with (from left to right) OS, DSS, and PFI. (D) Kaplan-Meier analysis of the correlation of XPO1 expression in GBM with PFI. (E) Kaplan-Meier analysis of the correlations of XPO1 expression in READ with OS (left) and DSS (right). (F) Kaplan-Meier analysis of the correlations of XPO1 expression in SARC with OS (left) and DSS (right). (G) Kaplan-Meier analysis of the correlation of XPO1 expression in KIRP with OS. (H) Kaplan-Meier analysis of the correlation of XPO1 expression in THYM with DSS. (I) Kaplan-Meier analysis of the correlation of XPO1 expression in STAD with DFI.




**Figure S2** Prognostic values of XPO1 based on the analysis of data from the Kaplan-Meier Plotter database. (A) Kaplan-Meier analysis of the correlations of XPO1 expression in LUSC with OS (left) and recurrence-free survival (RFS, right). (B) Kaplan-Meier analysis of the correlations of XPO1 expression in hepatocellular carcinoma (HCC) with OS (left) and RFS (right). (C) Kaplan-Meier analysis of the correlations of XPO1 expression in SARC with OS (left) and RFS (right). (D) Kaplan-Meier analysis of the correlations of XPO1 expression in pancreatic ductal adenocarcinoma (PDAC) with OS (left) and RFS (right). (E) Kaplan-Meier analysis of the correlations of XPO1 expression in UCEC with OS (left) and RFS (right). (F) Kaplan-Meier analysis of the correlations of XPO1 expression in papillary renal cell carcinoma (PRCC) with OS (left) and RFS (right). (G) Kaplan-Meier analysis of the correlation of XPO1 expression in LUAD with OS. (H) Kaplan-Meier analysis of the correlation of XPO1 expression in esophageal squamous cell carcinoma (ESCC) with OS. (I) Kaplan-Meier analysis of the correlation of XPO1 expression in esophageal adenocarcinoma (EAC) with OS. (J) Kaplan-Meier analysis of the correlation of XPO1 expression in gastric adenocarcinoma (GA) with RFS. (K) Kaplan-Meier analysis of the correlation of XPO1 expression in READ with OS. (L) Kaplan-Meier analysis of the correlation of XPO1 expression in paraganglioma(PGL) with OS.



**Figure S3** Correlations of XPO1 expression with expression levels of highly mutated genes (supplementary to *Figure 6*). Correlations of XPO1 expression with expression levels of the top 30 highly mutated genes in (A) ACC, (B) BRCA, (C) DLBC, (D) ESCA, (E) HNSC, (F) KICH, (G) KIRC, (H) KIRP, (I) LGG, (J) LIHC, (K) LUAD, (L) LUSC, (M) OV, (N) PAAD, (O) PCPG, (P) SARC, (Q) SKCM, (R) STAD, (S) THCA, (T) THYM, (U) UCS, and (V) UVM. Circle size indicates the magnitude of the P value and shade indicates the magnitude of the Spearman's rank correlation coefficient.





**Figure S4** Correlations of XPO1 expression with stromal and immune scores (supplementary to *Figure 7*). Correlations of XPO1 expression with ESTIMATE-calculated immune score (left) and stromal score (right) in (A) CESC, (B) BLCA, (C) BRCA, (D) ESCA, (E) HNSC, (F) KIRP, (G) LAML, (H) LIHC, (I) LUAD, (J) OV, (K) PCPG, and (L) SKCM. (M) Correlation of XPO1 expression with stromal score in (M) TGCT. Correlations of XPO1 expression with immune score in (N) TH1M, (O) UCS, (P) COAD, (Q) MESO, and (R) READ.